1. Linifanib: current status and future potential in cancer therapy.

    Expert Review of Anticancer Therapy 15(6):677 (2015) PMID 25936222

    Angiogenesis is one of the major mechanisms controlling tumor proliferation and metastatic spreading. Targeting of pro-angiogenic factors and their downstream effectors represents an appealing therapeutic option in the treatment of different cancer types. Linifanib (ABT-869) is a novel tyrosine-...
  2. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

    The Lancet 385(9980):1863 (2015) PMID 25740286

    Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing. We aimed to address these questions in terms of improvement...
  3. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.

    Cell Reports 11(4):564 (2015) PMID 25892239

    Understanding the molecular pathways that contribute to the aggressive behavior of HER2-positive breast cancers may aid in the development of novel therapeutic interventions. Here, we show that CDCP1 and HER2 are frequently co-overexpressed in metastatic breast tumors and associated with poor pa...
  4. Adjuvant ovarian suppression in premenopausal breast cancer.

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901438

  5. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  6. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  7. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

    Oncotarget 6(4):2315 (2015) PMID 25537513

    Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer thr...
  8. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

    Oncotarget 6(4):2315 (2015) PMID 25537513

    Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer thr...
  9. A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.

    Breast Journal 21(3):241 (2015) PMID 25772707

    Metastatic breast cancer (MBC) patients derive benefit from chemotherapy, but options become limited after several prior chemotherapeutic regimens. Oral etoposide (VP-16) has previously been found to be clinically active in MBC patients in phase II trials. However, with increasing availability o...
  10. Clinical utility of exemestane in the treatment of breast cancer.

    International Journal of Women s Health 7:551 (2015) PMID 26064072 PMCID PMC4455847

    Breast cancer is the most prevalent cancer in women, causing a significant mortality worldwide. Different endocrine strategies are available for the treatment of hormone-sensitive breast cancer, including antiestrogen tamoxifen and fulvestrant, as well as third-generation aromatase inhibitors (A...
  11. Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

    The Breast 23(5):690 (2014) PMID 24985755

  12. Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

    The Breast 23(5):690 (2014) PMID 24985755

  13. 2013 San Antonio Breast Cancer Symposium.

    Expert Opinion on Pharmacotherapy 15(8):1191 (2014) PMID 24697336

    The San Antonio Breast Cancer Symposium is considered by researchers and physicians involved in breast cancer management as one of the most important international events on the subject. A dense program of plenary presentations of novel findings, main lectures, poster discussions and displays, i...
  14. 2013 San Antonio Breast Cancer Symposium.

    Expert Opinion on Pharmacotherapy 15(8):1191 (2014) PMID 24697336

    The San Antonio Breast Cancer Symposium is considered by researchers and physicians involved in breast cancer management as one of the most important international events on the subject. A dense program of plenary presentations of novel findings, main lectures, poster discussions and displays, i...
  15. Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up.

    CardioVascular and Interventional Radiology 37(1):193 (2014) PMID 23652416

    This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresp...
  16. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

    The Breast 23(1):44 (2014) PMID 24210572

    Five to 10% of women with newly diagnosed breast cancer have synchronous metastases (de novo stage IV). A further 20% will develop metastases during follow-up (recurring stage IV). We compared the clinical outcomes of women with HER2-positive metastatic breast cancer (MBC) receiving first-line t...
  17. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

    The Breast 23(1):44 (2014) PMID 24210572

    Five to 10% of women with newly diagnosed breast cancer have synchronous metastases (de novo stage IV). A further 20% will develop metastases during follow-up (recurring stage IV). We compared the clinical outcomes of women with HER2-positive metastatic breast cancer (MBC) receiving first-line t...
  18. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

    Molecular Oncology 8(1):20 (2014)

    In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2-targeting agents without chemotherapy (CT) in HER2-positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique ...
  19. Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up.

    CardioVascular and Interventional Radiology 37(1):193 (2014) PMID 23652416

    This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresp...
  20. Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up.

    CardioVascular and Interventional Radiology 37(1):193 (2014) PMID 23652416

    This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresp...